Ojai Energetics claims to have assembled the most comprehensive core cannabis IP portfolio in the industry and one of the largest in the psychedelics industry.
Ojai Energetics (OE), a Californian company that has focused on research and development of novel cannabis and psychedelic compounds and therapies since 2014, enlisted the patent law firm Wilson Sonsini to begin amassing the most comprehensive core cannabis IP portfolio in the industry and one of the largest in the psychedelics industry.
“[Ojai Energetics] is the patent creation and commercialisation company you’ve never heard of, until now, and the company designed it that way,” said Will Kleidon, founder and CEO of Ojai Energetics.
OE’s patents cover the superior delivery of cannabinoids with minimal onset time while yielding significantly higher bioavailability than traditional formulations. The company’s IP also covers other formulations across beverages, cosmetics, skin care, and shampoos, along with patents for modular hemp processing and industrial applications including hemp building materials, supercapacitors, and carbon nano-sheets.
Amidst plans to further commercialise its IP and complete its latest funding round, OE will offer its cannabis strain-specific, one-minute onset CBD beverages at the inaugural Medical Psychedelic Series in Davos, Switzerland, while showcasing three of the company’s psychedelic IP portfolio covering LSD, ketamine and psilocybin/psilocin assets.
“In addition to cannabis, OE has built one of the most robust psychedelics patent portfolios in the world,” OE’s senior vice president of Business Development, Andre Bourque said. “Our patents cover drug delivery platform composition of matter for all psychedelic drugs, such as tryptamine class compounds (LSD, psilocybin, DMT), phenethylamine class compounds (mescaline, MDMA), and ketamine to name a few.”
“In this case, we have three patents available that outperform what’s available on the market and are seeking to add them to the right portfolio for well-intentioned therapeutic research and development,” Bourque continued.